Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Celgene's share price is ARS0.00.
Celgene's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 was ARS1,048.60. Hence, Celgene's PS Ratio for today is 0.00.
Good Sign:
Celgene Corp stock PS Ratio (=4.83) is close to 10-year low of 4.83
The historical rank and industry rank for Celgene's PS Ratio or its related term are showing as below:
BUE:CELG'
s PS Ratio Range Over the Past 10 Years
Min: 7.54 Med: 9.32 Max: 11.48
Current: 4.83
During the past 13 years, Celgene's highest PS Ratio was 11.48. The lowest was 7.54. And the median was 9.32.
BUE:CELG's PS Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 2.24
vs BUE:CELG: 4.83
Celgene's Revenue per Sharefor the
three
months ended in Sep. 2019 was ARS346.52.
Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 was ARS1,048.60.
During the past 12 months, the average Revenue per Share Growth Rate of Celgene was 15.30% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 20.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 21.40% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 23.30% per year.
During the past 13 years, Celgene's highest 3-Year average Revenue per Share Growth Rate was 241.30% per year. The lowest was -42.80% per year. And the median was 32.20% per year.
Back to Basics: PS Ratio
Celgene (BUE:CELG) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Celgene PS Ratio Related Terms
Celgene PS Ratio Historical Data
* Premium members only.
The historical data trend for Celgene's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Celgene's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celgene PS Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celgene's PS Ratio distribution charts can be found below:
* The bar in red indicates where Celgene's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Celgene's Share Price of today is ARS0.00. Celgene's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS1,048.60.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Celgene (BUE:CELG) has a PS Ratio of 0.00 as of Jul. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Celgene and its competitors. Over the past decade, Celgene's PS Ratio has ranged from 7.54 to 11.48.
Is Celgene's PS Ratio too high?
Celgene's current PS Ratio is 0.00. Over the past 10 years, this metric has ranged from a low of 7.54 to a high of 11.48. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's PS Ratio compare to GILD and BIIB?
Celgene's PS Ratio of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median PS Ratio is 2.24. Historically, Celgene's own PS Ratio has ranged from 7.54 to 11.48 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.24, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Celgene and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current PS Ratio of 0.00. The current PS Ratio is 0.00. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Celgene (BUE:CELG), the current PS Ratio is 0.00 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:CELG has been successfully added to your 
